DK1149167T3 - Virusvaccine - Google Patents

Virusvaccine

Info

Publication number
DK1149167T3
DK1149167T3 DK99963478T DK99963478T DK1149167T3 DK 1149167 T3 DK1149167 T3 DK 1149167T3 DK 99963478 T DK99963478 T DK 99963478T DK 99963478 T DK99963478 T DK 99963478T DK 1149167 T3 DK1149167 T3 DK 1149167T3
Authority
DK
Denmark
Prior art keywords
sequence variants
viral
mixture
vaccine
protein
Prior art date
Application number
DK99963478T
Other languages
Danish (da)
English (en)
Inventor
Michael Schreiber
Original Assignee
Strathmann Ag & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Strathmann Ag & Co filed Critical Strathmann Ag & Co
Application granted granted Critical
Publication of DK1149167T3 publication Critical patent/DK1149167T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK99963478T 1999-02-12 1999-12-03 Virusvaccine DK1149167T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19907485A DE19907485B4 (de) 1999-02-12 1999-02-12 Virus-Vakzine
PCT/EP1999/009759 WO2000047223A2 (de) 1999-02-12 1999-12-03 Virus-vakzine

Publications (1)

Publication Number Publication Date
DK1149167T3 true DK1149167T3 (da) 2004-07-12

Family

ID=7898389

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99963478T DK1149167T3 (da) 1999-02-12 1999-12-03 Virusvaccine

Country Status (12)

Country Link
US (1) US20060222665A1 (enExample)
EP (1) EP1149167B1 (enExample)
JP (1) JP2002536418A (enExample)
CN (1) CN1268748C (enExample)
AT (1) ATE260978T1 (enExample)
AU (1) AU1976100A (enExample)
DE (2) DE19907485B4 (enExample)
DK (1) DK1149167T3 (enExample)
ES (1) ES2216619T3 (enExample)
PT (1) PT1149167E (enExample)
WO (1) WO2000047223A2 (enExample)
ZA (1) ZA200106155B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118874B2 (en) * 1998-10-09 2006-10-10 Variation Biotechnologies Inc. Immunogenic formulation and process for preparation thereof
EP1311278A4 (en) * 2000-08-07 2005-01-05 Sloan Kettering Institutefor C METHOD AND IMMUNIZATION COMPOSITION USING MIXED POOLS OF NUCLEIC ACIDS OR MUTED PEPTIDES
DE10218129A1 (de) * 2002-04-23 2003-11-20 Univ Ruprecht Karls Heidelberg Genetischer Impfstoff gegen RNA-Virus-Infektionen
BRPI0504117A (pt) * 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
DK2170384T3 (en) 2007-07-02 2016-07-25 Etubics Corp METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AN adenovirus vector for use in higher vaccination
CN101591379B (zh) * 2008-05-27 2017-01-18 中国疾病预防控制中心性病艾滋病预防控制中心 基于eiav减毒活疫苗的氨基酸突变而构建的抗hiv疫苗
CN103865945A (zh) * 2010-02-10 2014-06-18 中国人民解放军军事医学科学院放射与辐射医学研究所 Tat核心肽段在制备高效、可溶性表达的外源蛋白中的应用
US9605276B2 (en) 2012-08-24 2017-03-28 Etubics Corporation Replication defective adenovirus vector in vaccination
US10245313B2 (en) * 2014-10-24 2019-04-02 Versitech Limited DNA motif compounds and methods for inducing specific antibodies and cellular immunity
WO2016187151A1 (en) * 2015-05-18 2016-11-24 Calimmune, Inc. Methods of discriminating between hiv-1 and lentiviral vectors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL89118A0 (en) * 1988-02-03 1989-08-15 Microgenesys Inc Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
US5851813A (en) * 1990-07-12 1998-12-22 President And Fellows Of Harvard College Primate lentivirus antigenic compositions
FR2677363A1 (fr) * 1991-06-07 1992-12-11 Pasteur Institut Compositions a base de peptides multiepitopiques, leur procede d'obtention et leurs applications, notamment en tant que vaccins.
WO1994022917A1 (en) * 1993-04-05 1994-10-13 University Of Massachusetts Medical Center Cross-reactive influenza a immunization
AU6829494A (en) * 1993-08-02 1995-02-28 Chiron Corporation Recombinant constructs using replacement sequences in hypervariable regions
US5741492A (en) * 1996-01-23 1998-04-21 St. Jude Children's Research Hospital Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses

Also Published As

Publication number Publication date
ES2216619T3 (es) 2004-10-16
DE59908783D1 (de) 2004-04-08
JP2002536418A (ja) 2002-10-29
AU1976100A (en) 2000-08-29
EP1149167A2 (de) 2001-10-31
US20060222665A1 (en) 2006-10-05
PT1149167E (pt) 2004-07-30
CN1268748C (zh) 2006-08-09
EP1149167B1 (de) 2004-03-03
ZA200106155B (en) 2002-08-05
DE19907485B4 (de) 2008-01-17
DE19907485A1 (de) 2000-09-28
WO2000047223A2 (de) 2000-08-17
WO2000047223A3 (de) 2000-11-16
CN1348496A (zh) 2002-05-08
ATE260978T1 (de) 2004-03-15

Similar Documents

Publication Publication Date Title
Feng et al. HIV-1 nucleocapsid protein induces" maturation" of dimeric retroviral RNA in vitro.
RU2468080C2 (ru) Новый класс терапевтических белковых молекул
CY1107818T1 (el) Hiv-1 tat, ή παραγωγα αυτου για προφυλακτικο και θεραπευτικο εμβολιασμο
ES2140418T3 (es) Flavivirus quimericos y/o flavivirus de crecimiento restringido.
Gopi et al. Click chemistry on azidoproline: high-affinity dual antagonist for HIV-1 envelope glycoprotein gp120
WO2002022686A3 (en) Defensin-antigen fusion proteins
DE59908783D1 (de) Virus-vakzine
MXPA00006263A (es) Inmunogenos anti-retrovirales, su preparacion y su uso.
ATE293169T1 (de) Latency associated peptide von tgf-beta um pharmazeutisch aktive proteine latent zu machen
BG60255B1 (bg) Метод за получаване на пептиди
Conley et al. Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens
WO2001043693A3 (en) Polynucleotide vaccines expressing codon optimized hiv-1 nef and modified hiv-1 nef
BR9204851A (pt) Antigeno de HIV e processo para sua produçao molécula de DNA recombinante, reagente para diagnóstico e vacina para sindrome da imunodeficiência adquirida
WO2002016409A3 (en) Vaccine immunogens comprising disulphide bridged cyclised peptide and use thereof in the treatment of allergies
Ni et al. Rational design of highly potent HIV-1 fusion inhibitory proteins: implication for developing antiviral therapeutics
RU2005123050A (ru) Супер-антигенные фьюжн-белки и их использование
WO2003077838A3 (en) Hiv-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and immunogens
WO1998052603A3 (en) An influenza enveloped dna vaccine
ATE447008T1 (de) Rre und cte umfassende gentechnische konstrukte und zusammensetzungen und verwendungen davon
GB2336844A (en) Anti-hiv peptides and proteins
WO1998042847A3 (de) Papillomvirus-hauptcapsid-proteins und deren verwendung in diagnose, therapie und vakzinierung
WO2004108886A3 (en) Anti-hiv-1 compounds based upon a conserved amino acid sequence shared by gp160 and the human cd4 protein
NZ296304A (en) Hepatitis c vaccine components
Wahren et al. Immune responses to the HIV rev regulatory gene
RU2346044C2 (ru) ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pBMC-gp140(A)-hum